Advertisement

Histochemistry

, Volume 100, Issue 5, pp 393–398 | Cite as

Do neuroendocrine cells in human prostate cancer express androgen receptor?

  • J. L. M. Krijnen
  • P. J. A. Janssen
  • J. A. Ruizeveld de Winter
  • H. van Krimpen
  • F. H. Schröder
  • T. H. van der Kwast
Originals

Abstract

The presence of androgen receptors (AR) in neuroendocrine cells was investigated in benign tissue of 10 prostatectomy specimens, in 12 prostatic adenocarcinomas with focal neuroendocrine differentiation and in 1 case of a pure neuroendocrine small cell carcinoma of the prostate. Neuroendocrine cells were defined by their reactivity with an antibody to chromogranin A. Monoclonal antibody F39.4 directed against the amino-terminal domain of the AR molecule was used to detect AR. AR and chromogranin A were simultaneously visualized with a double immunofluorescence technique. The results indicate that chromogranin positive cells in both benign and malignant prostatic tissue lack detectable expression of AR. No effect of endocrine therapy was noted. These results are in agreement with the hypothesis that prostatic neuroendocrine tumour cells represent an androgen insensitive cell population, which incidentally may expand to replace the androgen-sensitive tumour cell population during androgen ablation therapy.

Keywords

Androgen Receptor Small Cell Carcinoma Human Prostate Cancer Neuroendocrine Cell Neuroendocrine Differentiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrahamsson PA, Falkmer S, Fält K, Grimelius L (1989) The course of neuroendocrine differentiation in prostatic carcinomas. Pathol Res Pract 185:373–380Google Scholar
  2. Cohen RJ, Glezerson G, Haffejee Z, Afrika D (1990) Prostatic carcinoma: Histological and immunological factors affecting prognosis. Br J Urol 66:405–410Google Scholar
  3. Concolino G, Marocchi A, Margiotta G, Conti C, Di Silverio F, Tenaglia R, Ferraro F, Bracci U (1982) Steroid receptors and hormone responsiveness of human prostatic carcinoma. Prostate 3:475–482Google Scholar
  4. DeLellis RA, Tischler AS, Wolfe HJ (1984) Multidirectional differentiation in neuroendocrine neoplasms. J Histochem Cytochem 32:899–904Google Scholar
  5. Di Sant'Agnese PA (1992) Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23:287–296Google Scholar
  6. Gallee MPW, Van Vroonhoven CCJ, Van der Korput JAGM, Van der Kwast TH, Ten Kate FJW, Romijn JC, Trapman J (1986) Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82. Prostate 9:33–45Google Scholar
  7. Gorelic LS, Lamm DL, Ramzy I, Radwin HM, Shain SA (1987) Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients. Cancer 60:211–219Google Scholar
  8. Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128:335–340Google Scholar
  9. Martelli A, Soli M, Berovich E, Prodi G, Grilli S, De Giovanni C, Galli MC (1980) Correlation between clinical response to endocrine therapy and occurrence of receptors in human prostatic cancer. Urology 16:245–249Google Scholar
  10. Masai M, Sumiya H, Akimoto S, Yatani R, Chang C, Liao S, Shimazaki J (1990) Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17:293–300Google Scholar
  11. Nakada SY, Di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett ATK, Abrahamsson P-A (1993) The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 53:1967–1970Google Scholar
  12. Paulson DF (1983) Lesson 17: prognostic factors in androgen independent prostatic carcinoma. American Urological Association Update Ser 2:1–8Google Scholar
  13. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW (1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254:1636–1639Google Scholar
  14. Roy JY, Têtu B, Ayala AG, Ordonez NG (1987) Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 59:977–982Google Scholar
  15. Ruizeveld de Winter JA, Trapman J, Brinkmann AO, Boersma WJA, Mulder E, Schröder FH, Claassen E, Van der Kwast ThH (1990) Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 161:329–332Google Scholar
  16. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, Van der Kwast TH (1991) Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 39:927–936Google Scholar
  17. Schron DS, Gipson T, Mendelsohn G (1984) The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer 53:2478–2480Google Scholar
  18. Stratton M, Evans DJ, Lampert JA (1986) Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment. J Clin Pathol 39:750–756Google Scholar
  19. Ten Kate FJW, Gallee MPW, Schmitz PIM, Jöbsis AC, Van der Heul RO, Prins MEF, Blom JHM (1986) Controversy in grading of prostatic carcinoma: interobserver reproducibility of five different grading systems. World J Urol 4:147–152Google Scholar
  20. Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis C, Ordonez NG (1987) Small cell carcinoma of the prostate. I. A clinicopathologic study of 20 cases. Cancer 59:1803–1809Google Scholar
  21. Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM (1988) Neuroendocrine differentiation in prostatic carcinomas: a retrospective autopsy study. Arch Pathol Lab Med 112:1100–1105Google Scholar
  22. Van Haaften-Day C, Raghavan D, Russell P, Wills EJ, Gregory P, Tilley W, Horsfall DJ (1987) Xenografted small cell undifferentiated cancer of the prostate: possible common origin with prostatic adenocarcinoma. Prostate 11:271–279Google Scholar
  23. Van der Kwast ThH, Schalken J, Ruizeveld de Winter JA, Van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189–193Google Scholar
  24. Zegers ND, Claassen E, Neelen C, Mulder E, Van Laar JH, Voorhorst MM, Berrevoets CA, Brinkmann AO, Van der Kwast ThH, Ruizeveld de Winter JA, Trapman J, Boersma WJA (1991) Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multiassay performance following the synthetic peptide strategy. Biochim Biophys Acta 1073:23–32Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • J. L. M. Krijnen
    • 1
  • P. J. A. Janssen
    • 1
  • J. A. Ruizeveld de Winter
    • 1
  • H. van Krimpen
    • 1
  • F. H. Schröder
    • 2
  • T. H. van der Kwast
    • 1
  1. 1.Department of PathologyErasmus UniversityRotterdamThe Netherlands
  2. 2.Department of UrologyErasmus UniversityRotterdamThe Netherlands

Personalised recommendations